Webinar: Investing in Process Development for Increased MSC Production in Stirred Tank Bioreactors


 Watch Now


 Webinar Overview

Industry trends in regenerative medicine highlight a critical need for closed cell culture systems that support scalable manufacturing of adherent cell therapies. Typical static in vitro culture methods, however, are often too cumbersome and inefficient to support commercial scale production of mesenchymal stem/stromal cells (MSCs). Single-use stirred tank bioreactor systems are a platform that can address this limitation and have been proven effective for microcarrier-based production of adherent cell therapies. Implementation of optimized process control strategies for parameters such as dissolved oxygen (DO) and agitation rate are key to making an efficient transition from planar culture to stirred tank bioreactors.

In this industry webinar, we present a stepwise approach to process development for MSC expansion in a small-scale single-use bioreactor. Case studies focus on strategies to optimize DO control and agitation rates for bone marrow derived MSCs in microcarrier culture, highlighting improvements in process efficiency.

Case study 1: Examining the impact different gassing methods have on DO control and whether hypoxic growth conditions affect MSC function

Case study 2: Demonstrating the application of Zwietering’s equation for suspension of solids to overcome scaling challenges often associated with microcarrier culture in stirred tanks.

Strategies to further improve the seeding process for bioreactor culture will also be reviewed. Identifying optimal seeding and process control strategies for microcarrier-based bioreactor expansion of adherent cells is paramount for the development of robust cell therapy manufacturing platforms.

From this webinar, you will learn about:

  • Process development approaches for production scale-up of mesenchymal stem cells (MSCs)
  • Implementing single-use, closed systems for manufacturing cell therapies
  • Case studies focusing on strategies to optimize DO control and agitation rates for microcarrier-based cultures
Speaker Bio
Kara Levine, Ph.D.
Head of Systems and Tools
Cell Therapy Bioprocessing
Dr. Kara Levine heads the Systems and Tools team within the Cell Therapy Bioprocessing group of MilliporeSigma. She has been a part of the company for more than seven years. In her current role she manages product development, process development and application projects, providing expertise in cell culture, media formulation and single use technologies and tools. Prior to her current role, Kara was a project manager overseeing single use device development. Before that, she supported chromatography product development as a R&D scientist and was the technical lead driving optimization of cell culture media products for monoclonal antibody production. Kara earned her Ph.D. from the University of Massachusetts Medical School (UMASS) in the fields of biochemistry and cell biology, with a focus on understanding the protein structure function relationship amongst membrane uniporters.